INDIANAPOLIS, United States — October 30, 2026. American pharmaceutical giant Eli Lilly has reported another blockbuster quarter, with revenue climbing 39% to approximately $24.4 billion as worldwide demand for its diabetes and obesity medicines Mounjaro and Zepbound continues to transform the global drug industry.
The October 29 earnings announcement showed that Lilly’s two leading tirzepatide products generated more than $16 billion in combined sales during the third quarter alone, underscoring the extraordinary commercial scale of the market for treatments targeting diabetes and obesity.
Mounjaro revenue jumped 65% to $10.72 billion, while Zepbound sales grew 49% to $5.35 billion.
The performance exceeded Wall Street expectations and prompted management to raise its full-year revenue forecast to between $91 billion and $92 billion.
But the financial report also contained a surprising development.
Despite record sales, Eli Lilly lowered its full-year adjusted earnings-per-share guidance to $35–$36, primarily because of charges associated with acquisitions and research programs.
Meanwhile, early sales of the company’s new oral obesity medicine Foundayo fell below analyst expectations, and competition with Denmark’s Novo Nordisk is intensifying.
The biggest question is whether Eli Lilly can maintain its remarkable growth while investing billions in the next generation of weight-loss medicines—or whether increasing competition, lower prices and development costs will eventually challenge its dominance.
Eli Lilly beats Wall Street as quarterly revenue climbs 39%
Lilly reported worldwide third-quarter revenue of $24.397 billion, compared with $17.601 billion in the same period of 2025.
That represents an increase of approximately 39%.
The company said unit volume rose 53%, reflecting growing demand across its product portfolio.
However, realized selling prices declined 15%, meaning higher sales volume was partly offset by reduced average revenue per unit.
The distinction is essential for understanding the company’s performance.
Lilly is selling substantially more medicine, but not necessarily receiving a higher average price for each unit.
According to CNBC, analysts surveyed by LSEG had expected revenue of approximately $22.61 billion.
The actual result exceeded that forecast by around $1.8 billion.
Adjusted earnings reached $7.48 per share, ahead of the $6.26 estimate cited in CNBC’s report.
On a reported accounting basis, earnings were $7.22 per share.
The result demonstrates the scale of Lilly’s commercial expansion, although adjusted earnings and reported earnings are not interchangeable financial measures.
Mounjaro becomes a $10.7-billion quarterly blockbuster
Mounjaro was the largest contributor to Lilly’s third-quarter revenue.
Worldwide sales reached approximately $10.723 billion, up 65% from $6.515 billion a year earlier.
US revenue increased 41% to approximately $5 billion.
Sales outside the United States rose 93% to approximately $5.7 billion.
The international performance reflects strong demand for tirzepatide, the active ingredient in Mounjaro.
The treatment is marketed for type 2 diabetes in the United States, while regional approvals and branding arrangements differ across international markets.
The product’s commercial success demonstrates how medicines acting on the GIP and GLP-1 pathways have become central to the pharmaceutical industry’s growth.
These treatments help regulate blood glucose and influence appetite-related biological pathways.
However, Mounjaro is a prescription medicine.
It should not be presented as appropriate for everyone seeking weight loss, nor should its commercial success be confused with a guarantee of individual treatment results.
Appropriate treatment depends on approved indications, medical assessment and potential risks.
Zepbound sales climb to $5.35 billion
Zepbound, Lilly’s tirzepatide product marketed for weight management in the United States, generated approximately $5.352 billion in worldwide third-quarter revenue.
That represents a 49% increase compared with the same period last year.
US sales reached approximately $5.3 billion.
The increase reflects strong demand, expanding treatment access and higher prescription volumes.
Zepbound and Mounjaro contain the same active ingredient but are marketed under different brands and regulatory indications.
Together, the two medicines generated approximately $16.075 billion during the quarter.
That accounts for about 66% of Lilly’s total revenue.
This concentration highlights both the company’s commercial strength and an important long-term risk.
A large share of Lilly’s financial performance depends on the continued success of two closely related products.
Changes in competition, reimbursement, pricing or manufacturing capacity could therefore have substantial consequences.
Higher volume offsets falling drug prices
One of the most revealing details in Lilly’s financial statement is the divergence between product volume and pricing.
Worldwide sales volume rose 53%, while realized prices declined 15%.
US revenue increased 34% to approximately $15.1 billion.
The company reported that US volume increased 41%, partly offset by a 7% decline in realized prices.
Outside the United States, revenue rose 47% to approximately $9.3 billion.
International volume increased 76%, while realized prices fell 29%.
The decline in international pricing partly reflected the inclusion of Mounjaro on China’s National Reimbursement Drug List earlier in 2026.
Public reimbursement can expand patient access, but it may involve lower negotiated selling prices.
For Lilly, the challenge is maintaining strong volume growth while adjusting to different healthcare payment systems.
For patients and governments, the larger question is whether rising competition and expanded coverage will make treatments more accessible and affordable.
Foundayo’s early sales disappoint Wall Street
Lilly’s expansion beyond injectable treatments is becoming an increasingly important part of its strategy.
The company reported third-quarter sales of approximately $184 million for Foundayo, its oral obesity medicine containing orforglipron.
The result was below some analyst expectations.
However, the product is still in its early commercial launch period.
Lilly’s management emphasized that underlying demand in the United States was growing and that prescription trends remained encouraging.
The distinction matters because early product launches can be affected by distribution, insurance coverage, reimbursement arrangements and the pace at which physicians adopt new treatments.
A disappointing initial sales figure does not establish that a medicine has failed commercially.
Nevertheless, Foundayo faces significant competition.
Novo Nordisk has also entered the oral obesity treatment market with its Wegovy pill.
Daily pills could appeal to patients who prefer not to use injections, but convenience alone does not guarantee market leadership.
Effectiveness, safety, price and insurance coverage will all influence adoption.
Why Eli Lilly lowered earnings guidance despite higher sales
Perhaps the most surprising part of Lilly’s announcement was its updated annual guidance.
Management raised its 2026 revenue forecast from $85 billion–$87 billion to $91 billion–$92 billion.
The midpoint therefore increased by $5.5 billion.
However, Lilly reduced its non-GAAP earnings-per-share forecast from $35.50–$36.50 to $35.00–$36.00.
That might appear contradictory.
But the explanation lies primarily in the accounting treatment of acquired research and development.
Lilly reported approximately $4.57 per share in acquired in-process research-and-development charges during the third quarter, compared with $0.71 per share a year earlier.
The company said stronger underlying performance increased its annual EPS expectations by $4.07 at the midpoint.
But the additional acquisition-related charges more than offset that improvement.
As a result, the headline EPS guidance fell.
The adjustment should therefore not be described as evidence that demand for Mounjaro and Zepbound has weakened.
Rather, it reflects the financial consequences of Lilly’s investment in other pharmaceutical development programs.
Net profit rises despite acquisition-related charges
Lilly reported quarterly net income of approximately $6.45 billion, up 16% from $5.58 billion a year earlier.
Reported earnings per share increased from $6.21 to $7.22.
The company also recorded significant expenses associated with research acquisitions.
These charges reduced reported and adjusted earnings under the company’s stated accounting methods.
Such investments may provide long-term opportunities if acquired medicines succeed in clinical development.
But pharmaceutical research carries substantial uncertainty.
A promising scientific program can require years of trials before receiving approval.
Some candidates may never reach the market.
For shareholders, the challenge is deciding whether today’s spending will produce enough future commercial value to justify its cost.
Lilly and Novo Nordisk are battling for the next obesity breakthrough
The company’s strong quarterly earnings come during an increasingly competitive period for obesity medicines.
Novo Nordisk, the Danish manufacturer of Wegovy and Ozempic, remains one of Lilly’s major rivals.
Both companies are investing in new medicines designed to improve treatment effectiveness, convenience and tolerability.
One emerging area involves amylin, a hormone associated with appetite regulation and feelings of fullness.
WWC ONE MEDIA previously examined this competition in Lilly and Novo Bet on Amylin as Next Obesity-Drug Battleground After GLP-1 Boom.
The report explored Lilly’s experimental EloraTZP combination, which combines the investigational amylin drug eloralintide with tirzepatide.
The highest-dose combination produced an average 23.3% body-weight reduction in a Phase 2b trial involving adults with obesity or overweight and type 2 diabetes.
But greater weight reduction was also associated with treatment discontinuations and gastrointestinal side effects.
Lilly plans larger trials to better establish effectiveness and safety.
Those results remain experimental and should not be interpreted as regulatory approval.
Retatrutide could become Lilly’s next major growth driver
Another important medicine in Lilly’s development pipeline is retatrutide.
The experimental treatment acts on three hormone pathways: GIP, GLP-1 and glucagon.
The company reported positive topline findings from a head-to-head Phase 3 study comparing retatrutide with Ozempic 2 milligrams in adults with type 2 diabetes.
Lilly has also reported substantial weight reduction in earlier studies.
The scientific program represents a potential opportunity to expand its treatment portfolio beyond existing tirzepatide medicines.
But retatrutide remains investigational.
Clinical studies must establish the treatment’s benefit-risk profile, and regulatory authorities must review the evidence before it can be approved.
It would therefore be premature to characterize retatrutide as an already available replacement for Mounjaro, Zepbound or competing treatments.
The next stage of the obesity-drug market may depend on a wider range of options rather than a single dominant medicine.
Novo Nordisk’s CagriSema illustrates the competitive challenge
Novo Nordisk is also advancing its experimental CagriSema combination.
The drug combines semaglutide with cagrilintide, an investigational amylin analogue.
WWC ONE MEDIA covered recent findings in Novo Nordisk’s Experimental CagriSema Shows 25% Average Weight Loss in Women — But a Major FDA Decision and Rival Drug Remain the Biggest Tests.
The reported 25% average weight loss came from an exploratory analysis of women participating in a larger clinical trial.
It reflected specific assumptions about continuing treatment.
It was not a newly completed study conducted only among women, nor does it establish that CagriSema is superior to all available obesity medicines.
In a separate head-to-head trial, CagriSema failed to demonstrate non-inferiority to tirzepatide.
These contrasting results illustrate why pharmaceutical competition cannot be reduced to comparing headline weight-loss percentages from unrelated studies.
Trial design, patient characteristics, duration, treatment dosing and adverse effects all matter.
For Lilly, maintaining its competitive position will require continued clinical progress alongside commercial expansion.
Medicare coverage is creating another growth opportunity
Expanded insurance coverage has become a major factor influencing demand for obesity treatment.
Reuters reported that Lilly’s participation in a Medicare-related pilot offering eligible beneficiaries certain weight-loss medicines for $50 per month has added more than 500,000 customers.
The figure indicates that reimbursement arrangements can significantly influence demand.
But the benefit should not be interpreted as a universal $50 price available to everyone.
Eligibility, coverage terms and out-of-pocket costs depend on the specific program.
The broader issue remains affordability.
Prescription obesity medicines can be expensive without insurance or subsidy support.
For Lilly, expanded coverage can increase patient access and support higher treatment volumes.
However, negotiated reimbursement may also contribute to lower average realized selling prices.
This creates a trade-off between broader access and revenue per prescription.
Lilly invests in manufacturing to support future demand
The company continues expanding its manufacturing capabilities to meet demand for existing and future medicines.
Its October earnings release highlighted new production investments in Texas and Virginia.
Management also pointed to the importance of strengthening drug manufacturing and technology capabilities.
Pharmaceutical production requires extensive quality controls, specialized facilities and regulatory compliance.
For injectable therapies, manufacturing capacity can become a significant constraint when demand rises quickly.
Increasing capacity may allow companies to supply more patients and reduce shortages.
But building facilities also requires major investment and time.
New manufacturing capacity does not guarantee that future demand will remain at current growth rates.
Lilly must balance the possibility of continued expansion against the risks of overinvesting.
Other medicines are becoming more important to Lilly’s future
Although Mounjaro and Zepbound dominate the company’s financial results, Lilly is also pursuing growth in oncology, immunology and neuroscience.
Kisunla, the company’s Alzheimer’s disease treatment, generated approximately $193 million in quarterly revenue.
Ebglyss, a treatment for certain patients with atopic dermatitis, generated approximately $202 million.
Jaypirca revenue increased to approximately $228 million.
Lilly also reported regulatory progress involving diabetes, cancer and other therapeutic areas.
These developments could help diversify its revenue base over time.
But the current numbers remain much smaller than sales from the two leading tirzepatide brands.
The company’s dependence on diabetes and obesity products will remain a major consideration for investors.
Pharmaceutical innovation involves financial risks beyond obesity
Eli Lilly’s acquisition spending reflects the industry’s continuing effort to develop new treatments across multiple disease areas.
Other major pharmaceutical companies face similar challenges.
WWC ONE MEDIA examined drug-development risks in Merck and Moderna’s Personalized Cancer Vaccine Shows Major Promise — But a Six-Week Manufacturing Challenge Could Determine How Fast Patients Get It.
That report explored the challenges of clinical validation, regulatory approval and specialized production for an experimental cancer therapy.
The technology is different from Lilly’s obesity medicines.
Nevertheless, it illustrates a common pharmaceutical business reality: promising research and substantial investment do not automatically guarantee approved products or commercial success.
Companies must sustain research spending while continuing to meet regulatory and manufacturing requirements.
Lilly’s acquisition-related charges should be considered in that context.
What Lilly’s results mean for the Philippines
The rapid expansion of obesity and diabetes medicines carries implications for healthcare markets worldwide, including the Philippines.
Growing pharmaceutical investment may eventually create additional treatment options.
However, product approvals, insurance coverage, pricing and local distribution vary by country.
Medicines approved in the United States should not automatically be assumed to have identical approved indications or commercial availability in the Philippines.
For patients, the important questions concern clinical suitability, affordability and safe access to regulated treatments.
For healthcare policymakers, the growth of expensive chronic-disease medicines raises issues involving reimbursement, equitable access and long-term healthcare spending.
Strong sales figures demonstrate commercial demand, but they do not establish that these medicines are accessible to every patient who may benefit.
Why investors remain optimistic despite the lower EPS outlook
Eli Lilly shares rose more than 6% following the earnings announcement, according to Reuters.
The reaction suggests investors placed substantial weight on the company’s strong revenue growth and raised sales forecast.
The underlying performance of its major products remained robust.
Mounjaro and Zepbound continued generating large increases in worldwide sales.
The updated revenue guidance also exceeded earlier company expectations.
But market enthusiasm should not obscure potential risks.
Investors must consider drug pricing, insurance reimbursement, competition, manufacturing costs, patent protection and the uncertainty of clinical development.
A substantial share-price increase following earnings does not guarantee continued appreciation.
The long-term outcome will depend on future financial results and how successfully Lilly executes its strategy.
The bigger question: Can Eli Lilly sustain its extraordinary growth?
Eli Lilly’s third-quarter results demonstrate the extraordinary commercial power of modern diabetes and obesity medicines.
Revenue increased 39%.
Mounjaro generated more than $10.7 billion in quarterly sales.
Zepbound added approximately $5.35 billion.
And the company raised its annual revenue guidance to as much as $92 billion.
These results confirm that strong global demand is continuing to reshape the pharmaceutical industry.
But future growth will become more complicated.
Average realized selling prices are declining.
Competition from Novo Nordisk and other drug developers is intensifying.
The company’s newer oral medicine has faced a slower-than-expected initial sales performance.
And research acquisitions are placing substantial charges on near-term earnings.
For investors, the real test is whether Lilly can use its current blockbuster success to create a broader, sustainable medicines business.
For patients, the question is whether scientific innovation can eventually translate into safer, effective and affordable treatment options.
Eli Lilly’s diabetes and obesity medicines are generating extraordinary revenue. But with drug prices under pressure and billions being invested in the next generation of treatments, its biggest challenge may be proving that today’s remarkable sales boom can deliver lasting value for patients and shareholders.
